Early market access of cancer drugs in the EU

Early market access of cancer drugs in the EU - PubMed

Patient access to new cancer drugs in the EU involves centralised licensing decisions by regulators as well as reimbursement recommendations in the context ...

Early market access of cancer drugs in the EU - Annals of Oncology

ABSTRACT. Patient access to new cancer drugs in the EU involves centralised licensing decisions by regulators as well as reimbursement recommendations in the ...

Access to oncology medicines in EU and OECD countries

Clinical trials and early access schemes offer patients an opportunity to receive new cancer medicines before regulatory approval and/or ...

Early market access of cancer drugs in the EU - ASU Library Catalog

Patient access to new cancer drugs in the EU involves centralised licensing decisions by regulators as well as reimbursement recommendations in the context ...

Access to oncology medicines in EU and OECD countries

... today. Despite the emergence of new oncology drugs, disparities in patient access—particularly through clinical trials and early...

Access to oncology medicines in EU and OECD countries

Despite the emergence of new oncology drugs, disparities in patient access—particularly through clinical trials and early access programs ...

Access to novel cancer medicines in four countries in Central and ...

Granting access to all novel medicines/indications is increasingly challenging because cancer medicine expenditure has been rising considerably in Europe in the ...

Time to access to novel anticancer drugs in Europe, a case study in ...

Access to anticancer medicines is dependent on regulatory procedures, HTA and price regulations. Germany has a fast market access for anticancer ...

Addressing Challenges in Access to Oncology Medicines

drug markets in 12 EU Member States (the United Kingdom, Germany, Finland ... Availability in the market is the first condition for access to medicines.

Differences in time to patient access to innovative cancer medicines ...

What's new? The first point of patient access to innovative medicines in Europe often occurs via early access programs (EAPs) or off-label use.

Time to reimbursement of novel anticancer drugs in Europe

We carried out a retrospective case study of anticancer medicines with European Union Market Access (EU-MA) and a positive Committee for ...

EU access to oncology medicines lags behind in the Netherlands

The expansion of national early access programs is one of several factors potentially influencing faster patient access to oncology medicines in ...

Early market access of oncologic drugs in the EU - ResearchGate

Patient access to new cancer drugs in the EU involves centralised licensing decisions by regulators as well as reimbursement recommendations in the context ...

EU HTA: Business as usual for market access strategy or time for ...

EU-wide Health Technology Assessment (HTA) is finally arriving in January 2025 for oncology drugs and ATMPs (Advanced therapy medicinal products).

Achieving equal and timely access to innovative anticancer drugs in ...

Restricted access limits oncologists' daily work in Eastern and South-Eastern EU countries. The roundtable discussion suggested considering the sequencing of ...

Advancing early access policies for innovative cancer drugs

While some European countries promoted early access schemes, Italy does not yet display a consolidated strategy for innovative drugs or for medicines targeting ...

Comparative study on anticancer drug access times between FDA ...

Thanks to the ATU, 25 of 36 drugs (69.4%) were made available early, on average 203 d (95% CI, 76–330) before FDA approval and on average 428 d ...

Role of the EMA specific marketing authorization procedures for ...

Studies also show that the average delay in time to market and patient access for innovative medicines in Europe is approximately 400 days but ...

Authorisation of medicines | European Medicines Agency (EMA)

All medicines must be authorised before they can be marketed and made available to patients. In the European Union (EU), there are two main routes for ...

LET'S TALK ACCESS! - Association of European Cancer Leagues

al., 'Early market access of cancer drugs in the EU.' Annals of ... melanoma in Europe per year do not have access to recommended first-line ...